Atossa Therapeutics Inc
ATOS
Company Profile
Business description
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Contact
1448 NW Market Street
Suite 500
SeattleWA98107
USAT: +1 206 588-0256
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
CSL’s latest result suggests the worst may be over
Relief replaces disappointment but can growth return?
stocks
ASX listed pharma boosted by weight loss drugs
GLP-1 momentum drives earnings for narrow moat share.
stocks
Nvidia earns upgrade as AI buildouts accelerate
Demand for AI infrastructure shows no signs of slowing.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,253.90 | 11.20 | -0.12% |
| CAC 40 | 8,401.18 | 81.31 | 0.98% |
| DAX 40 | 26,569.99 | 202.75 | 0.77% |
| Dow JONES (US) | 53,559.99 | 9.45 | -0.02% |
| FTSE 100 | 10,824.26 | 31.72 | 0.29% |
| HKSE | 25,584.79 | 19.05 | 0.07% |
| NASDAQ | 26,402.42 | 138.93 | -0.52% |
| Nikkei 225 | 65,018.46 | 1,387.10 | -2.09% |
| NZX 50 Index | 13,830.72 | 62.54 | 0.45% |
| S&P 500 | 7,711.76 | 19.23 | -0.25% |
| S&P/ASX 200 | 9,056.30 | 9.30 | -0.10% |
| SSE Composite Index | 3,952.18 | 4.39 | -0.11% |